Lohmander L S, Dalén N, Englund G, Hämäläinen M, Jensen E M, Karlsson K, Odensten M, Ryd L, Sernbo I, Suomalainen O, Tegnander A
Department of Orthopaedics, University Hospital, Lund, Sweden.
Ann Rheum Dis. 1996 Jul;55(7):424-31. doi: 10.1136/ard.55.7.424.
To assess the effects of intra-articular injections of hyaluronan on symptoms of knee osteoarthritis (OA).
Two hundred and forty patients with symptomatic, radiological knee OA were randomly assigned to treatment with weekly injections for five weeks with either 25 mg of high molecular weight hyaluronan or vehicle. Results were evaluated at weeks 1, 2, 3, 4, 5, 13, and 20 by visual analogue scales (pain, function, motion, activity), algofunctional index, and global evaluation by patient and investigator. Analysis was by "intention to treat', "per protocol', and area under the curve principles on unstratified patient groups and for patients stratified into four groups of equal size by age and baseline algofunctional index.
No serious side effects were reported. At 20 weeks both treatment groups were improved compared with baseline, with no difference between unstratified groups treated with placebo or hyaluronan. Comparison of treatment groups stratified by age and baseline algofunctional index revealed a significant difference in favour of hyaluronan over placebo (pain, activity, algofunctional index, global evaluations by patient and investigator) for patients older than 60 years and with a baseline algofunctional index greater than 10. There was no clinically relevant difference between the two treatments for the other three stratified subgroups of younger age or fewer symptoms. Similar results were obtained by area under the curve, intention to treat, and per protocol analysis.
Patients older than 60 years with knee osteoarthritis and with significant symptoms corresponding to an index of severity of knee disease of 10 or more, comprise the group most likely to benefit from treatment with intra-articular hyaluronan injections.
评估关节腔内注射透明质酸对膝骨关节炎(OA)症状的影响。
240例有症状、经影像学检查确诊的膝OA患者被随机分为两组,一组每周注射25mg高分子量透明质酸,另一组注射赋形剂,均持续注射5周。在第1、2、3、4、5、13和20周时,通过视觉模拟量表(疼痛、功能、活动度、日常活动)、algofunctional指数以及患者和研究者的整体评估来评价结果。分析采用“意向性治疗”、“符合方案集”以及曲线下面积原则,针对未分层的患者组以及按年龄和基线algofunctional指数分为四组且每组人数相等的患者进行分析。
未报告严重副作用。在第20周时,与基线相比,两个治疗组均有改善,使用安慰剂或透明质酸治疗的未分层组之间无差异。按年龄和基线algofunctional指数分层的治疗组比较显示,对于年龄大于60岁且基线algofunctional指数大于10的患者,透明质酸组在疼痛、活动度、algofunctional指数以及患者和研究者的整体评估方面显著优于安慰剂组。对于其他三个年龄较小或症状较轻的分层亚组,两种治疗方法在临床上无显著差异。通过曲线下面积、意向性治疗和符合方案集分析获得了相似的结果。
年龄大于60岁、患有膝骨关节炎且膝病严重程度指数为10或更高、有明显症状的患者,最有可能从关节腔内注射透明质酸治疗中获益。